Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults.

6533b7dafe1ef96bd126e398

RESEARCH PRODUCT

Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults.

Marc Fantino John A. Mikszta Hervé Bourhy Paul G. Alchas Philippe Emile Fernand Laurent

subject

Pilot Projects medicine.disease_cause Antibodies Viral MESH: Antibodies Neutralizing 0302 clinical medicine Rabies vaccine 030212 general & internal medicine Viral Mononegavirales Neutralizing Skin 0303 health sciences Intramuscular biology integumentary system Vaccination MESH: Rabies Vaccines MESH: Injections Intramuscular 3. Good health Vaccination Infectious Diseases Needles MESH: Young Adult [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology Molecular Medicine Female medicine.drug Adult Injections Intradermal Adolescent Rabies Injections Intramuscular Antibodies Injections 03 medical and health sciences Young Adult MESH: Rabies MESH: Skin Intradermal medicine Humans Seroconversion Lyssavirus 030304 developmental biology MESH: Adolescent MESH: Injections Intradermal MESH: Humans General Veterinary General Immunology and Microbiology business.industry Rabies virus Public Health Environmental and Occupational Health MESH: Adult MESH: Vaccination Rhabdoviridae biology.organism_classification medicine.disease MESH: Pilot Projects Virology Antibodies Neutralizing Rabies Vaccines MESH: Needles Immunology Rabies business MESH: Female MESH: Antibodies Viral

description

International audience; In the present pilot study, intradermal ID delivery systems with a BD microneedle from 1 to 3mm in length, and epidermal delivery (BD skin abrader) through abraded skin surface relative to standard intramuscular injection were evaluated. Circulating neutralizing antibodies were measured against the rabies virus after the Vero cells rabies vaccine was administered at D0, D7, D21 and D49. This clinical evaluation in 66 healthy volunteers shows that ID delivery using BD microneedle technology of 1/4 the IM antigen dose is safe, efficient and reliable, resulting in a protective seroconversion rate. In contrast, the epidermal delivery route did not produce an immune response against the rabies vaccine.

year	journal	country	edition	language
2010-08-16

10.1016/j.vaccine.2010.06.062 https://hal-pasteur.archives-ouvertes.fr/pasteur-01491942